Detalhe da pesquisa
1.
Epithelial SOX9 drives progression and metastases of gastric adenocarcinoma by promoting immunosuppressive tumour microenvironment.
Gut
; 72(4): 624-637, 2023 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-36002248
2.
Loss of ARID1A activates mTOR signaling and SOX9 in gastric adenocarcinoma-rationale for targeting ARID1A deficiency.
Gut
; 71(3): 467-478, 2022 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-33785559
3.
YAP1 mediates gastric adenocarcinoma peritoneal metastases that are attenuated by YAP1 inhibition.
Gut
; 70(1): 55-66, 2021 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-32345613
4.
Targeting cancer stem cells with a pan-BCL-2 inhibitor in preclinical and clinical settings in patients with gastroesophageal carcinoma.
Gut
; 70(12): 2238-2248, 2021 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-33487592
5.
Multiplex profiling of peritoneal metastases from gastric adenocarcinoma identified novel targets and molecular subtypes that predict treatment response.
Gut
; 69(1): 18-31, 2020 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31171626
6.
LncRNA PVT1 up-regulation is a poor prognosticator and serves as a therapeutic target in esophageal adenocarcinoma.
Mol Cancer
; 18(1): 141, 2019 10 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-31601234
7.
Galectin-3 expression is prognostic in diffuse type gastric adenocarcinoma, confers aggressive phenotype, and can be targeted by YAP1/BET inhibitors.
Br J Cancer
; 118(1): 52-61, 2018 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-29136404
8.
Nuclear expression of Gli-1 is predictive of pathologic complete response to chemoradiation in trimodality treated oesophageal cancer patients.
Br J Cancer
; 117(5): 648-655, 2017 Aug 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-28728163
9.
Correction to: LncRNA PVT1 up-regulation is a poor prognosticator and serves as a therapeutic target in esophageal adenocarcinoma.
Mol Cancer
; 20(1): 56, 2021 Mar 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-33766033
10.
A new intronic quantitative PCR method led to the discovery of transformation from human ascites to murine malignancy in a mouse model.
Front Oncol
; 13: 1062424, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-36865791
11.
Galectin-3 Cooperates with CD47 to Suppress Phagocytosis and T-cell Immunity in Gastric Cancer Peritoneal Metastases.
Cancer Res
; 83(22): 3726-3738, 2023 11 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-37738407
12.
Evolution of immune and stromal cell states and ecotypes during gastric adenocarcinoma progression.
Cancer Cell
; 41(8): 1407-1426.e9, 2023 08 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-37419119
13.
GRK3 is a poor prognosticator and serves as a therapeutic target in advanced gastric adenocarcinoma.
J Exp Clin Cancer Res
; 41(1): 257, 2022 Aug 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-35996148
14.
Patient-derived cell lines and orthotopic mouse model of peritoneal carcinomatosis recapitulate molecular and phenotypic features of human gastric adenocarcinoma.
J Exp Clin Cancer Res
; 40(1): 207, 2021 Jun 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-34162421
15.
An improved strategy for CRISPR/Cas9 gene knockout and subsequent wildtype and mutant gene rescue.
PLoS One
; 15(2): e0228910, 2020.
Artigo
em Inglês
| MEDLINE | ID: mdl-32053639
16.
PPARδ Interacts with the Hippo Coactivator YAP1 to Promote SOX9 Expression and Gastric Cancer Progression.
Mol Cancer Res
; 18(3): 390-402, 2020 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-31796534
17.
LncRNA PVT1 Is a Poor Prognosticator and Can Be Targeted by PVT1 Antisense Oligos in Gastric Adenocarcinoma.
Cancers (Basel)
; 12(10)2020 Oct 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-33076512
18.
Targeting Hippo coactivator YAP1 through BET bromodomain inhibition in esophageal adenocarcinoma.
Mol Oncol
; 14(6): 1410-1426, 2020 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-32175692
19.
YAP1-Mediated CDK6 Activation Confers Radiation Resistance in Esophageal Cancer - Rationale for the Combination of YAP1 and CDK4/6 Inhibitors in Esophageal Cancer.
Clin Cancer Res
; 25(7): 2264-2277, 2019 04 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30563933
20.
A Novel YAP1 Inhibitor Targets CSC-Enriched Radiation-Resistant Cells and Exerts Strong Antitumor Activity in Esophageal Adenocarcinoma.
Mol Cancer Ther
; 17(2): 443-454, 2018 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-29167315